Clinical trial: the efficacy, impact on quality of life, and safety and tolerability of prucalopride in severe chronic constipation – a 12‐week, randomized, double‐blind, placebo‐controlled study
Top Cited Papers
- 22 December 2008
- journal article
- research article
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 29 (3), 315-328
- https://doi.org/10.1111/j.1365-2036.2008.03884.x
Abstract
BACKGROUND: Chronic constipation may result in disabling symptoms, is often unsatisfactorily treated by laxatives and negatively impacts quality of life (QoL).\ud \ud AIM: A randomized, double-blind, placebo-controlled, phase III trial to evaluate the efficacy and safety of a selective, high-affinity 5-HT(4) receptor agonist, prucalopride, in patients with chronic constipation [or=3 SCBMs/week, averaged over 12 weeks. Other assessments included BM frequency, constipation-related QoL and symptoms and tolerability.\ud \ud RESULTS: Among 641 patients, significantly more patients taking prucalopride 2 or 4 mg (24%) than placebo (12%), achieved the primary efficacy endpoint (>or=3 SCBMs/week) or an increase of >or=1 SCBMs/week; 43% and 47% vs. 28% respectively. Prucalopride-treated patients also achieved significantly greater satisfaction with treatment and bowel function, and improved perception of constipation severity and constipation-related QoL, compared with placebo. Most frequent treatment-related adverse events were headache, abdominal pain, nausea and diarrhoea (mainly during day 1). There were no differences in comparison to placebo in the incidence of serious adverse effects or cardiovascular events.\ud \ud CONCLUSION: Over 12 weeks, prucalopride was effective and well tolerated in chronic constipation.Chronic constipation may result in disabling symptoms, is often unsatisfactorily treated by laxatives and negatively impacts quality of life (QoL).A randomized, double-blind, placebo-controlled, phase III trial to evaluate the efficacy and safety of a selective, high-affinity 5-HT(4) receptor agonist, prucalopride, in patients with chronic constipation [or=3 SCBMs/week, averaged over 12 weeks. Other assessments included BM frequency, constipation-related QoL and symptoms and tolerability.Among 641 patients, significantly more patients taking prucalopride 2 or 4 mg (24%) than placebo (12%), achieved the primary efficacy endpoint (>or=3 SCBMs/week) or an increase of >or=1 SCBMs/week; 43% and 47% vs. 28% respectively. Prucalopride-treated patients also achieved significantly greater satisfaction with treatment and bowel function, and improved perception of constipation severity and constipation-related QoL, compared with placebo. Most frequent treatment-related adverse events were headache, abdominal pain, nausea and diarrhoea (mainly during day 1). There were no differences in comparison to placebo in the incidence of serious adverse effects or cardiovascular events.Over 12 weeks, prucalopride was effective and well tolerated in chronic constipationThis publication has 42 references indexed in Scilit:
- The burden of constipation on quality of life: results of a multinational surveyAlimentary Pharmacology & Therapeutics, 2007
- Chronic constipation: a survey of the patient perspectiveAlimentary Pharmacology & Therapeutics, 2007
- Chronic constipation: advances in managementNeurogastroenterology & Motility, 2006
- Comparing SF-36 scores across three groups of women with different health profilesQuality of Life Research, 2005
- The Health-Related Quality of Life and Economic Burden of ConstipationPharmacoEconomics, 2005
- Epidemiology of Constipation in North America: A Systematic ReviewThe American Journal of Gastroenterology, 2004
- Health-related quality of life in functional GI disorders: focus on constipation and resource utilizationThe American Journal of Gastroenterology, 2002
- Psychological Morbidity in Women With Idiopathic ConstipationThe American Journal of Gastroenterology, 2000
- Epidemiology of Constipation (EPOC) Study in The United States: Relation of Clinical Subtypes to Sociodemographic FeaturesThe American Journal of Gastroenterology, 1999
- Quality of Life in Patients with Different Types of Functional ConstipationScandinavian Journal of Gastroenterology, 1997